• 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52[1]
   
• PREVENT is the largest ever study of a biologic in patients with nr-axSpA and underscores Novartis leadership in rheumatology[1]
   
• There are approximately 1.7 million patients with nr-axSpA in the EU and US[2]
   
• PREVENT adds to 5-year evidence in ankylosing spondylitis (AS) and is a step forward in providing patients with …

• Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting
• US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modeling significant cost savings for health systems
• Sandoz is the pioneer and a global leader in biosimilars, with eight approved biosimilars worldwide and more than 10 in the pipeline

Holzkirchen, November 12, 2019 – Sandoz, a Novartis division and a global …

• Planned acquisition reinforces Sandoz strategic focus on Japan
• Aspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brands
• Medicines complement Sandoz broad hospital portfolio and pipeline in Japan thereby expanding access to the hospital channel

Holzkirchen, Germany, November 11, 2019 – Sandoz today announced that it has entered into a binding agreement for the planned acquisition of the Japanese business of Aspen Global Incorporated …

• Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy
   
• With approval of Ziextenzo™ , Sandoz is first and only company to offer US physicians long- and short-acting filgrastim biosimilar treatment options
   
• With four US approved biosimilars, Sandoz is committed to expanding patient access, increasing healthcare savings and fueling innovation

Holzkirchen, Nov. 5, 2019 – Sandoz, a Novartis division and a global …

• Worldwide agreement with Polpharma Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS)
• RRMS affects ~85% of MS patients and can create a substantial social and economic burden on patients, their families and healthcare systems[1],[2]
• Natalizumab is fifth proposed biosimilar in-licensed by Sandoz in nine months, underscoring commitment to further grow pipeline through collaborations

Holzkirchen, Germany, September 3, 2019 …